Dr Peter Laslo

Group Leader/ Senior Fellow

(+44) 0113 343 8031

Summary: I lead the LICAP Myeloid Differentiation group.

Location: Wellcome Trust Brenner Building, Level 6, Room 6.1


Dr. Peter Laslo's main research interests are in understanding the molecular aetiology of myeloid-based diseases.

Dr. Laslo obtained his PhD in Australia studying Immunology with particular emphasis in the T-cell response during organ transplantation. His first post-doctoral training was in neuropathology and the disease AML where his focus was the understanding of why of two neuronal populations one was susceptible to the pathology and the other resistant.

Dr. Laslo began his second post-doctoral training at the University of Chicago in the field of molecular haematology. Here, the primary goal of his research focused on understanding the gene regulatory network that regulates myeloid development. His findings identified the molecular mechanism for the onset and resolution of mixed lineage patterns of gene expression within myeloid progenitors. He was among the first to accurately depict these molecular events and to assemble a mathematical model of this network.

Dr. Laslo established his independent research group at the Leeds Institute of Cancer Studies and Pathology in 2008. Naturally inspired by his training, the primary focus of the lab is to analyse the gene regulatory networks within the hematopoietic system and to develop dynamic models to depict these genetic processes. These networks consist of transcription factors, epigenetic regulators as well as miRNA molecules that, in co-operation with one another, will regulate cell fate choices. It is important to understand these networks as any dysregulation in one or more of these regulators can contribute to the pathology of myeloid disorders including leukemias, chronic inflammation and bone disorders.